AU2003291278A1 - Celecoxib prodrug - Google Patents

Celecoxib prodrug Download PDF

Info

Publication number
AU2003291278A1
AU2003291278A1 AU2003291278A AU2003291278A AU2003291278A1 AU 2003291278 A1 AU2003291278 A1 AU 2003291278A1 AU 2003291278 A AU2003291278 A AU 2003291278A AU 2003291278 A AU2003291278 A AU 2003291278A AU 2003291278 A1 AU2003291278 A1 AU 2003291278A1
Authority
AU
Australia
Prior art keywords
composition
compound
water
celecoxib
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003291278A
Other languages
English (en)
Inventor
Gary D. Ewing
Matthew J. Graneto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2003291278A1 publication Critical patent/AU2003291278A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
AU2003291278A 2002-11-12 2003-11-03 Celecoxib prodrug Abandoned AU2003291278A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42570302P 2002-11-12 2002-11-12
US60/425,703 2002-11-12
PCT/US2003/035222 WO2004043934A1 (en) 2002-11-12 2003-11-03 Celecoxib prodrug

Publications (1)

Publication Number Publication Date
AU2003291278A1 true AU2003291278A1 (en) 2004-06-03

Family

ID=32313040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003291278A Abandoned AU2003291278A1 (en) 2002-11-12 2003-11-03 Celecoxib prodrug

Country Status (17)

Country Link
US (1) US20040092566A1 (ko)
EP (1) EP1562910A1 (ko)
JP (1) JP2006508123A (ko)
KR (1) KR20050072823A (ko)
CN (1) CN1711247A (ko)
AR (1) AR042037A1 (ko)
AU (1) AU2003291278A1 (ko)
BR (1) BR0316155A (ko)
CA (1) CA2505635A1 (ko)
CO (1) CO5700738A2 (ko)
MX (1) MXPA05004991A (ko)
NO (1) NO20052813L (ko)
PL (1) PL376918A1 (ko)
RU (1) RU2005114398A (ko)
TW (1) TW200424179A (ko)
WO (1) WO2004043934A1 (ko)
ZA (1) ZA200503188B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303591A1 (en) * 2002-12-30 2004-07-29 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
WO2006055381A2 (en) * 2004-11-16 2006-05-26 Merck & Co., Inc. Prodrugs of (2r)-2-propyloctanoic acid for treatment of stroke
CN101805290A (zh) * 2010-04-01 2010-08-18 中国人民解放军第四军医大学 氨基磺酰吡唑类化合物及其用途
BRPI1003050B1 (pt) * 2010-08-04 2021-05-25 Universidade Federal De Minas Gerais Compostos derivados do ácido araquidônico substituídos com análogos de coxibes para tratamento de dor
KR101245078B1 (ko) * 2010-11-11 2013-03-18 부산대학교 산학협력단 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물
US9562015B2 (en) 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
CN104892514A (zh) * 2015-05-19 2015-09-09 广州诺威生物技术有限公司 一种咪唑类新化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69719496T2 (de) * 1996-04-12 2004-04-08 G.D. Searle & Co., Chicago N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULPHONYLPROPYLAMID und sein NATRIUMSALZ ALS PRO-PHARMAKON VON COX-2 INHIBITOREN

Also Published As

Publication number Publication date
RU2005114398A (ru) 2006-01-20
TW200424179A (en) 2004-11-16
PL376918A1 (pl) 2006-01-09
WO2004043934A1 (en) 2004-05-27
MXPA05004991A (es) 2005-08-02
NO20052813L (no) 2005-08-02
CA2505635A1 (en) 2004-05-27
AR042037A1 (es) 2005-06-08
KR20050072823A (ko) 2005-07-12
BR0316155A (pt) 2005-09-27
NO20052813D0 (no) 2005-06-10
ZA200503188B (en) 2006-11-29
JP2006508123A (ja) 2006-03-09
CN1711247A (zh) 2005-12-21
CO5700738A2 (es) 2006-11-30
US20040092566A1 (en) 2004-05-13
EP1562910A1 (en) 2005-08-17

Similar Documents

Publication Publication Date Title
AU777402B2 (en) Valdecoxib compositions
US20020049233A1 (en) Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor
EP1446118B1 (en) Oral dosage form of parecoxib
ZA200503188B (en) Celecoxib prodrug
EP1814517B1 (en) Nonaqueous liquid parenteral aceclofenac formulation
US20030232871A1 (en) Crystalline parecoxib sodium
JP2005509002A6 (ja) スルホンアミドプロドラックの経口剤形
US6864373B2 (en) Stable amorphous celecoxib composite and process therefor
AU2002352646A1 (en) Oral dosage form of a sulfonamide prodrug such as parecoxib
ZA200406788B (en) Crystalline parecoxib sodium
ZA200402728B (en) Intraordally disintegrating valdecoxib compositions prepared by spray drying process.

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period